TC
DMTX

TFS Capital’s Dimension Therapeutics, Inc DMTX Stock Holding History

TFS Capital’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,043
Closed -$61K – 1019
2016
Q4 		$61K Sell
14,043
-1,814
-11% -$9.65K 0.02% 677
2016
Q3 		$127K Sell
15,857
-20,884
-57% -$151K 0.03% 619
2016
Q2 		$220K Buy
+36,741
New +$280K 0.04% 694

Other funds holding DMTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TFS Capital's DMTX Position: Q1 2017 in Review

TFS Capital sold out of Dimension Therapeutics, Inc (DMTX) in Q1 2017, closing a stake of 14,043 shares — an estimated $61K sold.

TFS Capital first reported a position in DMTX in Q2 2016 and held it in 3 quarters. The position peaked at $220K in Q2 2016. 47 funds tracked by Wall St. Rank hold DMTX as of Q1 2017.

  • TFS Capital reported no remaining Dimension Therapeutics, Inc position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 14,043 Dimension Therapeutics, Inc shares in Q1 2017, an estimated $61K.
  • TFS Capital first reported a position in Dimension Therapeutics, Inc in Q2 2016 and held it in 3 quarters.
  • TFS Capital's Dimension Therapeutics, Inc position peaked at $220K in Q2 2016.
  • 47 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.